Expressions of SDHB and PDK1 and their clinical significance in nasopharyngeal carcinoma
1.Department of Otolaryngology, the Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325200; 2.Department of Otolaryngology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
LIN Sen1,CHEN Chongxi1,WANG Chunlei1, et al. Expressions of SDHB and PDK1 and their clinical significance in nasopharyngeal carcinoma[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(2): 91-.
Abstract：Objective: To investigate the expressions of SDHB and PDK1 and their correlation with the clinicopathological factors and prognosis in nasopharyngeal carcinoma (NPC). Methods: Immunohistochemstry was employed to analyze the expressions of SDHB and PDK1 in 78 specimens of NPC and 35 specimens of chronic nasopharyngitis tissues (CNT). Retsults: SDHB expression detected in 39.7% of the cancer tissues was significantly lower than those in 62.9% of nasopharyngitis tissues (x2=5.183, P<0.05). While PDK1 expression detected in 53.8% of the cancer tissues was significantly higher than those in 20.0% of nasopharyngitis tissues (x2=11.269, P<0.05). SDHB and PDK1 expressions were significantly associated with lymph node metastasis,tumor recurrence, cranial nerve palsy. however, there was no significant association between the expression and gender, age. Kaplan-Meter survival analysis showed that the survival rates of positive SDHB expression and negative PDK1 expression were higher than that of negative SDHB expression and positive PDK1 expression.Multivariate Cox regression analysis showed that the development of NPC, lymph node metastasis and recurrence were independent prognostic factors for NPC, but the expressions of SDHB and PDK1 were not an independent factor. Conclusion: The expressions of SDHB and PDK1 play an important role in the development of NPC, lymph node metastasis and recurrence. SDHB and PDK1 expressions may have an impact on prognosis, but it was not independent factor affecting the prognosis in pafients with NPC.
[1] Fishbein L, Merrill S, Fraker DL, et al. Inherited mutationsin pheochromocytoma and paraganglioma: why all patients should be offered genetic testing[J]. Ann Surg Oncol,2013,20(5): 1444-1450.
[2] van Hulsteijn LT, Dekkers OM, Hes FJ, et al. Risk of malignant paraganglioma in SDHB-mutation and SDHD-muta-tion carriers: a systematic review and meta-analysis[J]. J Med Genet, 2012, 49(12): 768-776.
[3] Patterson E, Webb R, Weisbrod A, et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma[J]. Endocr Relat Cancer,2012, 19(2): 157-166.
[4] Yang C, Matro JC, Huntoon KM, et al. Missense mutations in the human SDHB gene increase Protein degradation with-out altering intrinsic enzymatic function[J]. FASEB J, 2012,26(11): 4506-4516.
[5] Matro J, Giubellino A, Pacak K. Current and future thera-peutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors[J]. Horm Metab Res,2013, 45(2): 147-153.
[6] Fujiwara S, Kawano Y, Yuki H, et al. PDK1 inhibition is a novel therapeutic target in multiple myeloma[J]. Br J Cancer,2013, 108(1): 170-178.
[7] Hur H, Xuan Y, Kim YB, et al. Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential thera peutic target[J]. Int J Oncol, 2013, 42(1): 44-54.
[8] Peifer C, Alessi DR. New anti-cancer role for PDK1 inhibitors: preventing resistance to tamoxifen[J]. Biochem J, 2009, 417(1): 5-7.
[9] Wigfield SM, Winter SC, Giatromanolaki A, et al. PDK-1 regulates lactate production in hypoxia and is associated with poor prognosis in head and neck squamous cancer[J].Br J Cancer, 2008, 98(12): 1975-1984.
[10] Yu J, Chen KS, Li YN, et al. Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer[J]. Asian Pac J Cancer Prev, 2012, 13(8): 4147-4151.
